360 High-Risk Vulnerability Immunization Tool V2.0 vs HarfangLab Vulnerability Assessment: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

HarfangLab Vulnerability Assessment: Continuous vulnerability detection and prioritization using CVE database. built by HarfangLab. Core capabilities include Continuous automatic vulnerability detection without manual scanning, CVE database with constant updates from NIST, Daily vulnerability reporting..

Both serve the Vulnerability Assessment market but differ in approach, feature depth, and target audience.

360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. HarfangLab Vulnerability Assessment differentiates with Continuous automatic vulnerability detection without manual scanning, CVE database with constant updates from NIST, Daily vulnerability reporting.

360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). HarfangLab Vulnerability Assessment is developed by HarfangLab. Vendor maturity, funding stage, and team size can be important factors when evaluating long-term viability and support quality.

360 High-Risk Vulnerability Immunization Tool V2.0 and HarfangLab Vulnerability Assessment serve similar Vulnerability Assessment use cases: both are Vulnerability Assessment tools, both cover CVE. Review the feature comparison above to determine which fits your requirements.